Liquidia Corporation, trading on NASDAQ under the symbol LQDA, is a biopharmaceutical company focused on developing therapies for rare cardiopulmonary diseases. The company uses its proprietary PRINT Technology to create innovative treatments, particularly for pulmonary hypertension. Liquidia's competitors include other biopharmaceutical firms that specialize in similar therapeutic areas.On November 3, 2025, Jefferies upgraded Liquidia's stock to a "Buy" rating, with the stock priced at $25.22. This upgrade ...